Uncommon phenotypes of BCR::ABL1-positive chronic myelogenous leukemia.
PMID:
Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia.
PMID:
"Preleukemic or smoldering" chronic myelogenous leukemia (CML):BCR-ABL1 positive: A brief case report.
PMID:
Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring.
Jabbour E, Kantarjian H.
Am J Hematol. 2024 Nov;99(11):2191-2212. doi: 10.1002/ajh.27443. Epub 2024 Aug 2.
PMID:39093014
Chronic Myeloid Leukemia: A Review.
Jabbour E, Kantarjian H.
JAMA. 2025 May 13;333(18):1618-1629. doi: 10.1001/jama.2025.0220.
PMID:40094679
Uncommon phenotypes of BCR::ABL1-positive chronic myelogenous leukemia.
Jajosky AN, Lichtman MA.
Haematologica. 2025 Sep 1;110(9):1912-1920. doi: 10.3324/haematol.2025.287792. Epub 2025 May 15.
PMID:40371899
Response and Resistance to BCR-ABL1-Targeted Therapies.
Braun TP, Eide CA, Druker BJ.
Cancer Cell. 2020 Apr 13;37(4):530-542. doi: 10.1016/j.ccell.2020.03.006.
PMID:32289275
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions.
Osman AEG, Deininger MW.
Blood Rev. 2021 Sep;49:100825. doi: 10.1016/j.blre.2021.100825. Epub 2021 Mar 16.
PMID:33773846
The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.
Chronic Myeloid Leukemia in Children and Adolescents.
Gotesman M, Raheel S, Panosyan EH.
Adv Pediatr. 2023 Aug;70(1):145-155. doi: 10.1016/j.yapd.2023.04.002. Epub 2023 May 12.
PMID:37422292
Timing and trajectory of BCR::ABL1-driven chronic myeloid leukaemia.
Kamizela AE, Leongamornlert D, Williams N, Wang X, Nyamondo K, Dawson K, Spencer Chapman M, Guo J, Lee J, Mane K, Milne K, Green AR, Chevassut T, Campbell PJ, Ellinor PT, Huntly BJP, Baxter EJ, Nangalia J.